UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 717, 2026

Structure Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Cayman Islands		001-41608		98-1480821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Gateway Blvd., Suite 900

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (650) 457-1978

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name Of Each Exchange Trading Symbol(s)	On Which Registered
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share	GPCR	Nasdaq Global Market

Ordinary shares, par value $0.0001 per share*	True	Nasdaq Global Market*

* Not for trading, but only in connection with the registration of the American Depositary Shares

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 15.0107 ~~Entry~~Submission ~~into~~of Matters to a ~~Material~~Vote ~~Definitive~~of ~~Agreement~~Security Holders.

On ~~May 7~~June 17, 2026, Structure Therapeutics Inc. (the “Company”) ~~amended~~held ~~and~~its ~~restated~~2026 ~~that~~Annual ~~certain~~General ~~Sales~~Meeting ~~Agreement~~of ~~dated~~Shareholders ~~August 6, 2025~~ (the “~~Sales~~Annual ~~Agreement”~~General ~~and as amended and restated, the “Amended and Restated Sales Agreement~~Meeting”). ~~with~~As ~~Leerink~~of ~~Partners~~April 20, ~~LLC and Cantor Fitzgerald & Co. (collectively~~2026, the ~~“Sales~~record ~~Agents”),~~date ~~relating~~for to the ~~offer~~Annual ~~and~~General ~~sale~~Meeting, ~~of the Company’s American Depositary Shares (“ADSs”)~~213,213,565 ~~each representing three~~ ordinary shares, ~~$0.0001~~were ~~par~~outstanding ~~value per ordinary share. The Amended~~ and ~~Restated~~entitled ~~Sales~~to ~~Agreement~~vote ~~modifies~~at the ~~Sales~~Annual ~~Agreement~~General toMeeting. ~~remove~~A ~~the~~summary ~~aggregate~~of ~~offering~~the ~~amount~~matters ofvoted ~~ADSs~~upon ~~the~~by ~~Company~~shareholders ~~may~~at ~~offer~~the ~~and~~Annual ~~sell~~General ~~thereunder~~Meeting ~~(the~~is ~~“ATM~~set ~~Shares”)~~forth below.

~~The~~Proposal ~~foregoing~~1: ~~description~~Election of the Amended and Restated Sales Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amended and Restated Sales Agreement, which is attached as Exhibit 1.1 hereto and is incorporated by reference herein.Directors

~~Item~~Ted 2W.02 ~~Results~~Love M.D., Raymond Stevens, Ph.D. and Daniel G. Welch were elected as a Class III directors, to hold office until the 2029 Annual General Meeting of ~~Operations~~Shareholders and ~~Financial~~their ~~Condition~~successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

On May 7, 2026, the Company issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Name of Director Elected	Votes For		Votes Against		Abstentions		Broker Non-Votes
Ted W. Love, M.D.		164,241,780		533,358		172,641		-0-
Raymond Stevens, Ph.D.		164,373,741		400,929		173,109		-0-
Daniel G. Welch		161,336,058		3,429,342		182,379		-0-

~~The~~Proposal ~~information~~2: inRatification ~~this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes~~ of ~~Section~~Appointment 18 of ~~the Securities Exchange Act of 1934, as amended (the~~ ~~“Exchange~~Independent ~~Act”),~~Registered orPublic ~~otherwise~~Accounting subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.Firm

~~Item~~The ~~8.01~~Company’s ~~Other~~shareholders ~~Events~~ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

On May 7, 2026, in connection with Amended and Restated Sales Agreement, the Company filed a prospectus supplement (the “Prospectus Supplement”) to the prospectus filed on August 6, 2025 (the “Prospectus”) with the Securities and Exchange Commission as part of the Company’s Registration Statement on Form S-3ASR (File No. 333-289326). The Company filed the Prospectus Supplement to increase the ATM Shares available to be sold pursuant to the terms of the Amended and Restated Sales Agreement by an additional $150,000,000, for an aggregate offering price of up to $400,000,000.

Votes For				Votes Against				Abstentions				Broker Non-Votes
	164,767,215				20,784				159,780				-0-

~~The~~Proposal ~~Prospectus~~3: ~~Supplement~~Advisory ~~should~~vote beon ~~read in conjunction with~~ the ~~Prospectus, and~~compensation isof ~~qualified by reference thereto, except to~~ the ~~extent that the information therein amends or supersedes the information contained~~Company’s innamed ~~the~~executive ~~Prospectus. The Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus and any future amendments or supplements thereto.~~officers

AsOn ofan ~~the~~advisory ~~date~~basis, ofthe shareholders approved the ~~Prospectus~~compensation ~~Supplement,~~of the Company’s ~~previously sold~~named anexecutive ~~aggregate~~officers, ofas ~~3,040,000~~disclosed ~~ATM~~in ~~Shares~~the Company’s proxy statement for ~~gross~~the ~~proceeds~~Annual ofGeneral Meeting. ~~approximately~~The ~~$58,520,000~~voting ~~under~~results ~~the~~are ~~Sales~~as ~~Agreement.~~follows:

A copy of the opinion of Travers Thorp Alberga relating to the validity of the ATM Shares is attached as Exhibit 5.1 hereto.

Votes For				Votes Against				Abstentions				Broker Non-Votes
	158,547,441				6,187,647				212,691				-0-

~~Item 9.01 Financial Statements and Exhibits.~~SIGNATURES

~~(d)~~Pursuant ~~Exhibits~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit
	Structure Therapeutics Inc.
No.		Description
Date: June 18, 2026	By:	/s/ Matthew Lang
1.1		Amended and Restated Sales Agreement, by and among Structure Therapeutics Inc., Leerink Partners LLC and Cantor Fitzgerald & Co., dated May 7, 2026.
		Matthew Lang
5.1		Opinion of Travers Thorp Alberga.
		Chief Operating Officer and General Counsel
23.1		Consent of Travers Thorp Alberga (included in Exhibit 5.1).
99.1		Press Release dated May 7, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Structure Therapeutics Inc.
Date: May 7, 2026	By:	/s/ Raymond Stevens
		Raymond Stevens, Ph.D.
		Chief Executive Officer

Filing Compare · Structure Therapeutics Inc.